We are live on
!
Find out more
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
(+7%)
Cap. Flow
+$35.9M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
1
year
Top 20 Avg Time Held Equity + Options
1.1
years
Avg Time Held Equity only
1.8
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$59.7M |
| 2 |
Odyssey Therapeutics
ODTX
|
+$52.6M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$47.6M |
| 4 |
Cogent Biosciences
COGT
|
+$47.6M |
| 5 |
Humana
HUM
|
+$46.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$54.7M |
| 2 |
Danaher
DHR
|
+$50.4M |
| 3 |
Enliven Therapeutics
ELVN
|
+$50.2M |
| 4 |
Boston Scientific
BSX
|
+$48.8M |
| 5 |
Disc Medicine
IRON
|
+$48.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.03% |
| 2 | Miscellaneous | 2.97% |
No holdings matched the selected filter criteria.
Similar funds
OrbiMed's Q2 2026 Portfolio in Review
As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.
- OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
- OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
- OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
- OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
- OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
- OrbiMed opened 38 new positions and closed 23 in Q2 2026.
- OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.
Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.